Webinar: Clinical value of cystatin C in drug dosing

24. Feb 2021 | 5 min read

Webinar: Clinical value of cystatin C in drug dosing

Clinical value of predicting renal elimination of medications with cystatin C

Welcome to the fourth webinar in Gentian's cystatin C webinar series. Our US Product Specialist, Shanyil Wickramasinghe, will focus on two real-world scenarios to illustrate the clinical value of incorporating cystatin C testing into medication dosing and monitoring protocols:

  • Personalising chemotherapeutic interventions through co-reporting of cystatin C and creatinine-based eGFRs

  • Cystatin C-guided dosing of vancomycin: A novel approach to achieving trough concentrations among ICU patients

Data presented in this webinar is collected from publications of independent research1-10.

 

Watch the webinar here: 

Cystatin C and drugdosing_webinar 9102v01

Watch webinar here

Contact Gentian - Cystatin C

Get in touch with our Product Manager for cystatin C for product specification and pricing:

 

 

Cystatin C immunoassay brochure

 

References:

  1. McMahon, BA and MH Rosner. GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer, in Kidney360, 2020. 
  2. Santos, MLC et al. Nephrotoxicity in cancer treatment: An overview, in World J Clin Oncol, 2020. 
  3. Orth, M et al. Avoiding Insufficient Therapies and Overdosing with Co-Reporting eGFRs for Personalized Drug Therapy and Improved Outcomes, in ACHIEVING MEASURABLY BETTER HEALTHCARE PERFORMANCE, 2019.
  4. Frazee, EN et al. Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study, in Crit Care, 2014. 
  5. Begg, EJ, ML Barclay and CJ Kirkpatrick. The therapeutic monitoring of antimicrobial agents, in Br J Clin Pharmacol, 1999. 
  6. Levine, DP. Vancomycin: a history, in Clin Infect Dis, 2006. 
  7. FDA, Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Impact on Dosing, DHHS, Editor. 2020: www.fda.gov.
  8. Frazee, E et al. Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project, in Am J Kidney Dis, 2017.
  9. Kullar, R et al. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort, in Pharmacotherapy, 2012. 
  10. Lloyd-Smith, P et al. Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: assessing attributable cost and length of stay, in J Hosp Infect, 2013. 

You may also read


Diagnostic Efficiency - October 2021

Oct 14, 2021

Diagnostic Efficiency - October 2021

Diagnostic efficiency - Newsletter October 2021 Gentian is very pleased that we again can present our..

NKF-ASN Task Force: Recommends increased use of cystatin C

Sep 24, 2021

NKF-ASN Task Force: Recommends increased use of cystatin C

NKF-ASN Task Force: Recommends increased use of cystatin C as a confirmatory assessment of GFR The NKF-ASN..

Cystatin C at AACC 2021

Sep 21, 2021

Cystatin C at AACC 2021

Meet us at #2021 AACC - Booth #2741 For its fifth consecutive year, Gentian Diagnostics will be participating..